Immunexpress Declares SeptiCyte RAPID Testing for Paediatric Sepsis

Immunexpress Declares SeptiCyte RAPID Testing for Paediatric Sepsis

Healthcare Tech Outlook | Thursday, September 02, 2021

Rollie Carlson, CEO, Immunexpress

Immunexpress will be testing SeptiCyte RAPID test to diagnose pediatric sepsis in Queensland children.

FREMONT, CA: The SeptiCyte RAPID test will be examined in the diagnosis of pediatric sepsis in Queensland children, according to Immunexpress, Pty Ltd, a Brisbane-based molecular diagnostic organization.

The testing is partially financed by a Genomic Health Futures Mission grant from the Federal Government for collaborative work between The University of Queensland and Immunexpress. Early investment support with the initiative of Brian Flannery (Ilwella family office) and Australian Federal Government commercialization grants has been one of the cornerstones to the successful development of the SeptiCyte technology.

The paediatric sepsis research team, in collaboration with Associate Professor Luregn Schlapbach (Child Health Research Centre - The University of Queensland) and Dr Richard Brandon (co-founder and Chief Scientific Officer of Immunexpress), will use SeptiCyte RAPID screening on a near-patient testing platform (Biocartis Idylla) to conduct the study. SeptiCyte RAPID determines the likelihood of sepsis in children providing clinical symptoms of systemic inflammation, like fever or rapid breathing, using a small blood sample and a one-hour turnaround time.

According to Dr Brandon, Immunexpress was developed in Queensland, and now SeptiCyte technology is heading home. SeptiCyte LAB was approved by the FDA to be used in adults, whereas SeptiCyte RAPID, a wholly automated 2nd generation device, has received CE approval. It is therefore critical that the company establish SeptiCyte RAPID's clinical value in children. This change comes as a result of the relationship with The University of Queensland.

According to Associate Professor Schlapbach, the combined work's findings will help save the lives of critically ill children by enhancing sepsis diagnosis utilizing genetic technology. The importance of timely and correct identification of sepsis in the successful management of these patients cannot be overstated. Sepsis is still the most significant cause of death in children globally.

Weekly Brief